📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Window into the Mind: Handheld Spectroscopic Eye-safe Device (EyeD) for Neurodiagnostics

Lead Research Organisation: University of Glasgow
Department Name: School of Engineering

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
 
Description See report from lead partner (Birmingham) - EP/V029983/1
Exploitation Route See report from lead partner (Birmingham) - EP/V029983/1
Sectors Healthcare

Manufacturing

including Industrial Biotechology

 
Description See report from lead partner (Birmingham) - EP/V029983/1
First Year Of Impact 2024
Sector Healthcare,Manufacturing, including Industrial Biotechology
Impact Types Societal

Economic

 
Description Optos 
Organisation Optos plc
Department Optos
Country United Kingdom 
Sector Private 
PI Contribution The grant has led to important discussions with Optos (a company owned by Nikon) on Optoretinography (ORG) and a tomographic version (ORT) for the recording of optical signals caused by retinal neural function with the potential for the early detection and diagnosis of major eye diseases, such as glaucoma, AMD and retinal pathologies.
Collaborator Contribution The grant has led to important discussions with Optos (a company owned by Nikon) on Optoretinography (ORG) and a tomographic version (ORT) for the recording of optical signals caused by retinal neural function with the potential for the early detection and diagnosis of major eye diseases, such as glaucoma, AMD and retinal pathologies.
Impact None to date
Start Year 2022